 |
Pernix Therapeutics Completes Acquisition of Somaxon Pharmaceuticals, Inc.
Mar 6, 2013
|
14.7 KB |
|
| |
THE WOODLANDS, Texas--(BUSINESS WIRE)--
Pernix Therapeutics Holdings, Inc. ("Pernix") (NASDAQ: PTX) today
announced the completion of its acquisition of Somaxon Pharmaceuticals,
Inc. ("Somaxon") (NASDAQ: SOMX) following the approval of the
transaction by stockholders of Somaxon at the special meeting held on
...
|
|
Somaxon Pharmaceuticals Announces Settlement of Silenor Patent Litigation With Actavis
Feb 5, 2013
|
24.0 KB |
|
| |
SAN DIEGO, Feb. 5, 2013 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today announced that it has entered into a settlement agreement with Actavis Elizabeth LLC and Actavis Inc. to resolve pending patent litigation involving Silenor® 3 mg and 6 mg tablets.
The settlement agreement ...
|
|
Somaxon Announces That Paladin Labs Has Received Approval of New Drug Submission for Silenor (R) in Canada
Dec 17, 2012
|
23.9 KB |
|
| |
SAN DIEGO, Dec. 17, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX) today announced that its licensee Paladin Labs Inc. (TSX:PLB) has received approval from Health Canada of Paladin's New Drug Submission (NDS) for Silenor® (doxepin) for the treatment and symptomatic relief of insomnia characterized by frequent nocturnal aw...
|
|
Pernix Therapeutics Announces Agreement to Acquire Somaxon Pharmaceuticals, Inc.
Dec 11, 2012
|
21.8 KB |
|
| |
Somaxon Shareholders to Receive $25 Million in Pernix Common Stock
Pernix Management to Host a Conference Call Today at 9:00 a.m. EST
THE WOODLANDS, Texas & SAN DIEGO--(BUSINESS WIRE)--
Pernix Therapeutics Holdings, Inc. ("Pernix") (NYSE MKT: PTX) and
Somaxon Pharmaceuticals,...
|
|
Somaxon Pharmaceuticals Reports Third Quarter 2012 Financial Results
Oct 31, 2012
|
37.1 KB |
|
| |
Conference call scheduled today at 4:30 p.m. ET (1:30 p.m. PT);
Simultaneous webcast at http://investors.somaxon.com/eventdetail.cfm
SAN DIEGO, Oct. 31, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today reported its financial results for the third quarter ended September 30, ...
|
|
Somaxon Pharmaceuticals to Report Third Quarter 2012 Results and Conduct Conference Call on Wednesday, October 31
Oct 22, 2012
|
21.6 KB |
|
| |
SAN DIEGO, Oct. 22, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today announced that it will release its financial results for the third quarter ended September 30, 2012 on Wednesday, October 31, 2012 after the close of the U.S. financial markets. The Company will also conduct a conferen...
|
|
Somaxon Pharmaceuticals Approves 1-for-8 Reverse Stock Split and Decrease in the Number of Authorized Shares of Its Common Stock to 25,000,000 Shares
Oct 11, 2012
|
23.3 KB |
|
| |
SAN DIEGO, Oct. 11, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today announced that its Board of Directors approved a 1-for-8 reverse stock split of its common stock and a decrease in the number of authorized shares of its common stock from 100,000,000 to 25,000,000 shares. The reverse ...
|
|
Somaxon Pharmaceuticals to Present at the Stifel Nicolaus 2012 Healthcare Conference
Aug 27, 2012
|
21.4 KB |
|
| |
SAN DIEGO, Aug. 27, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today announced that Richard W. Pascoe, Somaxon's president and chief executive officer, will present at Stifel Nicolaus 2012 Healthcare Conference at the Four Seasons Hotel in Boston on Thursday, September 6, at 10:20 a.m. ...
|
|
Somaxon Pharmaceuticals Reports Second Quarter 2012 Financial Results
Aug 7, 2012
|
36.8 KB |
|
| |
Conference Call Scheduled Today at 4:30 p.m. ET (1:30 p.m. PT);
Simultaneous Webcast at http://investors.somaxon.com/eventdetail.cfm
SAN DIEGO, Aug. 7, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today reported its financial results for the second quarter ended June 30, 2012....
|
|
Somaxon Pharmaceuticals to Report Second Quarter 2012 Results and Conduct Conference Call on Tuesday, August 7
Jul 30, 2012
|
21.6 KB |
|
| |
SAN DIEGO, July 30, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today announced that it will release its second quarter financial results for the period ended June 30, 2012, on Tuesday, August 7, 2012 after the close of the U.S. financial markets. The Company will also conduct a conferen...
|
|
Somaxon Pharmaceuticals Completes $3.0 Million Registered Direct Offering
Jul 24, 2012
|
25.6 KB |
|
| |
SAN DIEGO, July 24, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today announced that it has completed its previously announced registered direct offering of approximately 9.4 million shares of its common stock and warrants to purchase up to approximately 4.7 million shares of its common ...
|
|
Somaxon Pharmaceuticals to Raise $3.0 Million in Registered Direct Offering
Jul 20, 2012
|
26.1 KB |
|
| |
SAN DIEGO, July 20, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today announced that it has entered into definitive agreements to sell approximately 9.4 million shares of its common stock and warrants to purchase up to approximately 4.7 million shares of its common stock to institutional...
|
|
Somaxon Pharmaceuticals Announces Settlement of Silenor Patent Litigation With Zydus
Jul 19, 2012
|
24.4 KB |
|
| |
SAN DIEGO, July 19, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today announced that it has entered into a settlement agreement with Cadila Healthcare Limited and Zydus Pharmaceuticals (USA), Inc. (collectively, "Zydus") to resolve pending patent litigation involving Silenor® 3 mg a...
|
|
Somaxon Pharmaceuticals Announces Settlement of Silenor Patent Litigation With Mylan and PAR
Jul 17, 2012
|
25.8 KB |
|
| |
SAN DIEGO, July 17, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today announced that it has entered into separate settlement arrangements with Mylan Inc. and its subsidiary, Mylan Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc. and its subsidiary Par Pharmaceutical, Inc. to ...
|
|
Somaxon Pharmaceuticals Reports First Quarter 2012 Financial Results
May 10, 2012
|
23.1 KB |
|
| |
Conference call scheduled today at 8:30 a.m. ET (5:30 a.m. PT);
Simultaneous webcast at http://investors.somaxon.com/eventdetail.cfm
SAN DIEGO--(BUSINESS WIRE)--
Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical
company, today reported its financial res...
|
|
Somaxon Pharmaceuticals to Report First Quarter 2012 Results and Conduct Conference Call on Thursday, May 10
Apr 30, 2012
|
10.5 KB |
|
| |
SAN DIEGO--(BUSINESS WIRE)--
Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical
company, today announced that it will release its first quarter ended
March 31, 2012 financial results on Thursday, May 10, 2012 before the
open of the U.S. financial markets. The Company will also conduct a
...
|
|
Somaxon and CJ CheilJedang Announce Silenor® Collaboration in South Korea
Apr 27, 2012
|
19.1 KB |
|
| |
SAN DIEGO & SEOUL, South Korea--(BUSINESS WIRE)--
Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) and CJ CheilJedang
Corporation today announced that they have entered into an exclusive
collaboration under which CJ CheilJedang will commercialize Silenor®
(doxepin) for the treatment of insomnia in South Korea.
...
|
|
Somaxon Reports Financial Results for Full Year and Fourth Quarter Ended December 31, 2011
Mar 8, 2012
|
30.4 KB |
|
| |
Conference call scheduled today at 4:30 p.m. ET (1:30 p.m. PT);Simultaneous
webcast at http://investors.somaxon.com/eventdetail.cfm
SAN DIEGO--(BUSINESS WIRE)--
Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical
company, today reported financial results ...
|
|
Somaxon Pharmaceuticals to Report Full Year and Fourth Quarter 2011 Results and Conduct Conference Call on Thursday, March 8
Feb 27, 2012
|
10.5 KB |
|
| |
SAN DIEGO--(BUSINESS WIRE)--
Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical
company, today announced that it will release its full year and fourth
quarter 2011 financial results on Thursday, March 8, 2012 after the
close of the U.S. financial markets. The Company will also conduct a
...
|
|
Paladin and Somaxon Announce Filing of New Drug Submission for Silenor®
Feb 22, 2012
|
17.4 KB |
|
| |
MONTREAL & SAN DIEGO--(BUSINESS WIRE)--
Paladin Labs Inc. (TSX:PLB) and Somaxon Pharmaceuticals, Inc. (Nasdaq:
SOMX) today announced that Paladin has filed a New Drug Submission (NDS)
that has been accepted for review by Health Canada for Silenor®
(doxepin) for the treatment and symptomatic relief of insomni...
|
|
|
